Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Liquidia will report its first quarter 2025 financial results on Thursday, May 8, 2025.
-
Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
-
Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
-
The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.
-
Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in 6MWD, cardiac effort and QoL.
-
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the full year ended December 31, 2024.
-
Liquidia has entered into a sixth amendment to its agreement with HealthCare Royalty to provide for up to an additional $100 million of financing.
-
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
-
Liquidia's Chief Executive Officer, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
-
Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024.